Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 19/20 | 0.71 |
| ▸ | GUCY1A2 | P33402 | 19/20 | 0.71 |
| ▸ | GUCY1A1 | Q02108 | 19/20 | 0.71 |
| ▸ | GUCY1B1 | Q02153 | 19/20 | 0.71 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.57 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.57 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.57 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.57 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.57 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15630817 | 0.91 | GUCY1B2 (0.71) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15630719 | 0.89 | GUCY1B2 (0.70) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL11067466 | 0.88 | GUCY1B2 (0.65) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1PSEN1 | |
| SCHEMBL11064908 | 0.85 | ATP4A (0.68) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1PSEN1 | |
| SCHEMBL15671364 | 0.85 | GUCY1B2 (0.67) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15630797 | 0.84 | GUCY1B2 (0.62) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL11067127 | 0.84 | ATP4A (0.58) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1PSEN1 | |
| SCHEMBL15665044 | 0.84 | GUCY1B2 (0.70) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| Hydrochloric Acid SCHEMBL15665679 | 0.84 | GUCY1B2 (0.66) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15630940 | 0.84 | GUCY1B2 (0.61) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447090-B2 | Imidazopyridine compounds | ASTELLAS PHARMA INC. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-9447090-B2 | Imidazopyridine compounds | ASTELLAS PHARMA INC. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-9447090-B2 | Imidazopyridine compounds | ASTELLAS PHARMA INC. (JP) | 2016-09-20 | — | — | US | disclosed |
| EP-2716642-B1 | IMIDAZOPYRIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-07-20 | — | — | EP | disclosed |
| US-9278968-B2 | Imidazopyridine compounds | ASTELLAS PHARMA INC. (JP) | 2016-03-08 | — | — | US | disclosed |
| US-9278968-B2 | Imidazopyridine compounds | ASTELLAS PHARMA INC. (JP) | 2016-03-08 | — | — | US | disclosed |
| US-20150232464-A1 | IMIDAZOPYRIDINE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2015-08-20 | — | — | US | disclosed |
| US-20150232464-A1 | IMIDAZOPYRIDINE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2015-08-20 | — | — | US | disclosed |
| WO-2014084312-A1 | IMIDAZOPYRIDINE COMPOUND | アステラス製薬株式会社 (JP) | 2014-06-05 | — | — | WO | disclosed |
| US-20140088080-A1 | IMIDAZOPYRIDINE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2014-03-27 | — | — | US | disclosed |
| US-20140088080-A1 | IMIDAZOPYRIDINE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2014-03-27 | — | — | US | disclosed |
| US-20140088080-A1 | IMIDAZOPYRIDINE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2014-03-27 | — | — | US | disclosed |
| EP-0033094-B1 | IMIDAZO(1,2-A)PYRIDINES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1984-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232464-A1 | IMIDAZOPYRIDINE COMPOUNDS | PRKG1, PDE3B, PDE3A | GUCY1B2 26/4885GUCY1A2 16/4885GUCY1A1 9/4885 |
| US-20140088080-A1 | IMIDAZOPYRIDINE COMPOUNDS | GUCY1A1, PDE2A, GUCY1A2 | GUCY1B2 9/4885GUCY1A2 3/4885GUCY1A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.